Testing bortezomib with temozolomide for grade-4 glioma that has come back
Official title: Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests two drugs given together in people whose grade-4 brain tumor has returned.
Read our full plain-language summary
What the trial team says
This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent grade-4 with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.
Key facts
- Registry number
- NCT03643549
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- Glioblastoma
Where it is running
This trial lists 2 sites.
-
Norway
- Haukeland University Hospital (Bergen)
- Oslo University Hospital (Oslo)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.